Home » Stocks » Mateon Therapeutics

Mateon Therapeutics Inc. (MATN)

Stock Price: $0.275 USD -0.012 (-4.18%)
Updated Jul 31, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 24.64M
Revenue (ttm) 340,855
Net Income (ttm) -10.32M
Shares Out 88.60M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $0.275
Previous Close $0.287
Change ($) -0.012
Change (%) -4.18%
Day's Open 0.290
Day's Range 0.250 - 0.295
Day's Volume 638,842
52-Week Range 0.076 - 0.350

More Stats

Market Cap 24.64M
Enterprise Value 25.57M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 88.60M
Float 55.88M
EPS (basic) -0.13
EPS (diluted) -0.13
FCF / Share -0.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 662,753
Short Ratio 8.04
Short % of Float 2.50%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 72.29
PB Ratio 1.68
Revenue 340,855
Operating Income -5.98M
Net Income -10.32M
Free Cash Flow -1.82M
Net Cash -931,871
Net Cash / Share -0.01
Gross Margin n/a
Operating Margin -1,755.43%
Profit Margin -3,027.60%
FCF Margin -534.02%
ROA -20.39%
ROE -117.42%
ROIC 321.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.275
Target: 0.55
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-------39.1%---
Gross Profit------0.100.16--
Operating Income-4.31-0.71-13.84-13.76-13.68-12.65-8.28-8.07-11.89-18.51
Net Income-6.64-0.71-13.81-13.65-13.65-12.65-8.28-8.08-9.65-23.77
Shares Outstanding59.966.1426.5526.5525.2016.972.801.470.930.33
Earnings Per Share-0.11-0.12-0.52-0.51-0.54-0.75-4.67-5.48-10.37-71.60
Operating Cash Flow-2.28-0.24-10.93-15.24-11.93-12.15-7.00-8.34-11.78-20.43
Capital Expenditures-----0.01-0.02-0.04-0.01--
Free Cash Flow-2.28-0.24-10.93-15.24-11.94-12.17-7.04-8.34-11.78-20.42
Cash & Equivalents0.080.001.1212.0527.2930.037.014.979.994.68
Total Debt0.96---------
Net Cash / Debt-0.880.001.1212.0527.2930.037.014.979.994.68
Book Value16.902.46-0.4812.5025.3529.006.044.558.80-5.26
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mateon Therapeutics Inc.
Country United States
Employees 13
CEO Vuong Trieu

Stock Information

Ticker Symbol MATN
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: MATN
IPO Date August 26, 1993


Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.